tiprankstipranks
Moleculin Biotech reports Q3 EPS (30c) vs. (15c) a year ago
The Fly

Moleculin Biotech reports Q3 EPS (30c) vs. (15c) a year ago

The company ended the quarter with $50.4M of cash. The company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&D rate of expenditures, beyond mid-2024.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles